Category:Adult
Status:Active
Hospitalized patients with pancreatic, stomach, ovarian or non-small lung cancer, or non-Hodgkin's lymphoma and who are at high risk for a venous thromboembolisn will be randomized to standard...
Diagnosis: GYN: Ovarian, Fallopian, Peritoneal Cancer, Other Cancers, Stomach Cancer, Non-Hodgkin's Lymphoma, Pancreatic Cancer
Phase: 2
Protocol Number: 15-547
A Study Of Blinatumomab For The Treatment Of Relapsed Or Refractory Indolent Non-Hodgkin Lymphoma
This research study is studying Blinatumomab as a possible treatment for Indolent Non-Hodgkin Lymphoma (NHL).
Diagnosis: Non-Hodgkin's Lymphoma
Phase: 2
Protocol Number: 16-118
The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.
Diagnosis: Solid Tumor/Phase I, Non-Hodgkin's Lymphoma
Phase: 1 / 2
Protocol Number: 15-207
This is a single arm, open-label, multi-center, phase 1/2 study, to determine the safety and efficacy of KTE-C19, an autologous anti-CD19 chimeric antigen receptor (CAR)-positive T cell therapy, in...
Diagnosis: Non-Hodgkin's Lymphoma
Phase: 1 / 2
Protocol Number: 15-238
This study will enroll approximately 50 adult subjects who have relapsed or refractory (r/r) iNHL to be infused with the study treatment, axicabtagene ciloleucel, to see if their disease responds t...
Diagnosis: Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 17-075
Axicabtagene Ciloleucel Expanded Access Study
This is a multicenter, open-label expanded access protocol for the treatment of subjects with relapsed/refractory transplant ineligible aggressive NHL.
Diagnosis: Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 17-125
This study will explore whether ivabradine lowers heart rate, and thus improves exercise capacity, in survivors of lymphoma who have an elevated resting heart rate as a side effect of prior radiati...
Diagnosis: Pediatric Non-Hodgkin Lymphoma, Pediatric Hodgkin Lymphoma, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 17-022
Lenalidomide and Blinatumomab in Treating Patients With Relapsed Non-Hodgkin Lymphoma
This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of imp...
Diagnosis: Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 17-720
The purpose of this study is to determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D) of TAK-659 and venetoclax when administered in combination in participants with non...
Diagnosis: Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 18-322
This research study will evaluate the safety and efficacy of a study drug called Umbralisib (also known as TGR-1202) alone as a possible treatment for Waldenstrom's Macroglobulinemia and Margi...
Diagnosis: Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 18-353
Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
To evaluate the safety and tolerability, find an appropriate dose to optimize safety and efficacy, and evaluate clinical activity of PBCAR0191 in subjects with relapsed/refractory (r/r) B-cell acut...
Diagnosis: Non-Hodgkin's Lymphoma, Leukemia/MDS
Phase:
Protocol Number: 18-608
DS-3201b in Participants With Lymphomas
DS-3201b is an experimental drug. It is not approved for regular use. It can only be used in clinical research. Adults with non-Hodgkin lymphoma (NHL) might be able to join this study if their dise...
Diagnosis: Non-Hodgkin's Lymphoma
Phase:
Protocol Number: 19-063